Siegfried AG Reports Continued Profitable Growth in H1 2025

In the first half of 2025, Siegfried AG demonstrated robust performance, successfully executing its strategic plan to achieve profitable growth. Despite challenges such as inflation in the U.S. and Germany and adverse currency fluctuations, the company maintained profitability, driven by strong demand for drug substances and products. The strategic EVOLVE+ plan continues to enhance Siegfried's focus on commercial, development, and operational excellence.

Financial highlights include net sales of CHF 619.5 million, marking a 1.6% increase in local currencies. Core EBITDA reached CHF 133.9 million, with a margin improvement to 21.6%. Despite a slight decrease in core net profit to CHF 65.7 million due to exchange rate impacts, operating cash flow grew significantly to CHF 149.6 million.

Strategic expansions are underway to support future growth, including increased production for sterile eye care at El Masnou and spray drying capacity at Barberà del Vallès. The Hameln site is also expanding with new manufacturing lines anticipated to contribute to revenue starting in 2026. Siegfried reaffirms its 2025 outlook of mid-single-digit sales growth and a core EBITDA margin above 22%.